SHAREHOLDER ALERT: Weiss Law Reminds SPPI, NATI, CCFN, and ARST Shareholders About Its Ongoing Investigations
SHAREHOLDER ALERT: Weiss Law Reminds SPPI, NATI, CCFN, and ARST Shareholders About Its Ongoing Investigations
NEW YORK, May 1, 2023 /PRNewswire/ --
纽约， 2023年5月1日 /PRNewswire/ —
If you own shares in any of the companies listed above and
would like to discuss our investigations or have any questions concerning
this notice or your rights or interests, please contact:
如果您拥有上述任何一家公司的股份，并且
想讨论我们的调查或者有任何疑问
本通知或您的权利或利益，请联系：
Joshua Rubin, Esq.
Weiss Law
305 Broadway, 7th Floor
New York, NY 10007
(212) 682-3025
(888) 593-4771
[email protected]
约书亚·鲁宾，Esq
Weiss Law
百老汇 305 号，7 楼
纽约，纽约 10007
(212) 682-3025
(888) 593-4771
[电子邮件保护]
Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI)
Spectrum Pharmicals公司（纳斯达克股票代码：SP
Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI), in connection with its acquisition by Assertio Holdings, Inc. ("Assertio"). Under the merger agreement, SPPI shareholders will receive 0.1783 shares of Assertio common stock for each of their shares, representing implied per-share consideration of $0.98 based upon Assertio's April 28, 2023 closing price of $5.51. Additionally, Spectrum Pharmaceuticals shareholders will receive one Contingent Value Right ("CVR") per Spectrum share entitling them to receive up to an additional $0.20 per share in total. If you own SPPI shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website:
Weiss Law正在调查董事会可能违反信托义务和其他违法行为 Spectrum Pharmicals公司（纳斯达克股票代码：SP，与Assertio Holdings, Inc.（“Assertio”）的收购有关。根据合并协议，SPPI股东每股将获得0.1783股Assertio普通股，相当于隐含的每股对价 0.98 美元 基于 Assertio 的 2023年4月28日 的收盘价 5.51 美元。此外，Spectrum Pharmicals股东每股Spectrum将获得一项或有价值权（“CVR”），使他们有权获得最多额外的价值权 0.20 美元 每股总计。如果您拥有SPPI股票并希望讨论此项调查或您的权利，请拨打上面列出的号码之一致电我们或访问我们的网站：
National Instruments Corporation (NASDAQ: NATI)
美国国家仪器公司（纳斯达克股票代码：NATI）
Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of National Instruments Corporation (NASDAQ: NATI) in connection with the proposed acquisition of NATI by Emerson Electric Co. Under the merger agreement, NATI shareholders will receive $60.00 in cash for each share of NATI owned. If you own NATI shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website:
Weiss Law正在调查董事会可能违反信托义务和其他违法行为 美国国家仪器公司（纳斯达克股票代码：NATI） 与艾默生电气公司拟议收购 NATI 有关根据合并协议，NATI股东将获得 60.00 美元 NATI拥有的每股股份均为现金。如果您拥有 NATI 股票并希望讨论本次调查或您的权利，请拨打上面列出的号码之一致电我们或访问我们的网站：
CCFNB Bancorp, Inc. (OTC: CCFN)
CCFNB Bancorp, Inc.（场外交易代码：CCFN）
Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of CCFNB Bancorp, Inc. (OTC: CCFN), in connection with the proposed merger of CCFN with Muncy Bank Financial, Inc. If you own CCFN shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website:
Weiss Law正在调查董事会可能违反信托义务和其他违法行为 CCFNB Bancorp, Inc.（场外交易代码：CCFN），关于CCFN与Muncy Bank Financial, Inc.的拟议合并。如果您拥有CCFN股票并希望讨论本次调查或您的权利，请拨打上面列出的号码之一致电我们或访问我们的网站：
Assertio Holdings, Inc. (NASDAQ: ASRT)
Assertio Holdings, Inc.（纳斯达克股票代码：AS
Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Assertio Holdings, Inc. (NASDAQ: ASRT), in connection with its proposed merger with Spectrum Pharmaceuticals, Inc. ("Spectrum Pharmaceuticals"). If you own ASRT shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website:
Weiss Law正在调查董事会可能违反信托义务和其他违法行为 Assertio Holdings, Inc.（纳斯达克股票代码：AS，涉及其与Spectrum Pharmicals, Inc.（“Spectrum Pharmicals, Inc.”如果您拥有 ASRT 股票并希望讨论此项调查或您的权利，请拨打上面列出的号码之一致电我们或访问我们的网站：
SOURCE Weiss Law
来源 Weiss Law